Literature DB >> 19874850

Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1.

Ferenc Kovács-Sólyom1, Andrea Blaskó, Roberta Fajka-Boja, Róbert L Katona, Lea Végh, Julianna Novák, Gábor János Szebeni, László Krenács, Ferenc Uher, Vilmos Tubak, Robert Kiss, Eva Monostori.   

Abstract

Galectin-1 (Gal-1) has been implicated in tumor progression partly via the induction of T-cell apoptosis. However the mechanism of Gal-1 induced T-cell death was mostly studied using recombinant, soluble Gal-1 producing controversial results. To explore the true mechanism of Gal-1 and hence tumor cell-induced T-cell death, we applied co-cultures of tumor cells and T-cells thus avoiding artificial circumstances generated using recombinant protein. T-cells died when co-cultured with Gal-1-expressing but survived with Gal-1 non-expressing tumor cells. Removing tumor cell surface Gal-1 or knocking down Gal-1 expression resulted in diminution of T-cell apoptosis. Gal-1 transgenic or soluble Gal-1 treated HeLa cells became cytotoxic. Stimulation of apoptosis required interaction between the tumor and T-cells, presence of p56lck and ZAP70, decrease of mitochondrial membrane potential and caspase activation. Hence tumor cell-derived Gal-1 might efficiently contribute to tumor self-defense. Moreover this system resolves the discrepancies obtained using recombinant Gal-1 in T-cell apoptosis studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874850     DOI: 10.1016/j.imlet.2009.10.003

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  36 in total

1.  Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Authors:  Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Heather C Flynn Gilmer; Darlene L Knutson; Richard G Vile
Journal:  Int J Cancer       Date:  2011-11-30       Impact factor: 7.396

2.  Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer.

Authors:  Dong Tang; Jun Gao; Sen Wang; Zhongxu Yuan; Nianyuan Ye; Yang Chong; Chuanqi Xu; Xuetong Jiang; Bin Li; Wei Yin; Yi Miao; Daorong Wang; Kuirong Jiang
Journal:  Tumour Biol       Date:  2015-03-01

3.  Synergistic induction of galectin-1 by CCAAT/enhancer binding protein alpha and hypoxia-inducible factor 1alpha and its role in differentiation of acute myeloid leukemic cells.

Authors:  Xu-Yun Zhao; Ke-Wen Zhao; Yi Jiang; Meng Zhao; Guo-Qiang Chen
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

4.  Galectins in hematological malignancies.

Authors:  Yves St-Pierre
Journal:  Am J Blood Res       Date:  2011-09-07

Review 5.  Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Authors:  Annie A Wu; Virginia Drake; Huai-Shiuan Huang; ShihChi Chiu; Lei Zheng
Journal:  Oncoimmunology       Date:  2015-04-01       Impact factor: 8.110

6.  Target-specific NMR detection of protein-ligand interactions with antibody-relayed 15N-group selective STD.

Authors:  Anasztázia Hetényi; Zsófia Hegedűs; Roberta Fajka-Boja; Éva Monostori; Katalin E Kövér; Tamás A Martinek
Journal:  J Biomol NMR       Date:  2016-11-24       Impact factor: 2.835

7.  Galectin 1 modulates plasma cell homeostasis and regulates the humoral immune response.

Authors:  Adrienne Anginot; Marion Espeli; Lionel Chasson; Stéphane J C Mancini; Claudine Schiff
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.422

8.  Identification of novel keloid biomarkers through profiling of tissue biopsies versus cell cultures in keloid margin specimens compared to adjacent normal skin.

Authors:  Barbara Shih; Duncan Angus McGrouther; Ardeshir Bayat
Journal:  Eplasty       Date:  2010-04-07

9.  Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression.

Authors:  Dong Tang; Jun Gao; Sen Wang; Nianyuan Ye; Yang Chong; Yuqin Huang; Jie Wang; Bin Li; Wei Yin; Daorong Wang
Journal:  Tumour Biol       Date:  2015-09-01

10.  Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.

Authors:  Gregory J Baker; Peter Chockley; Viveka Nand Yadav; Robert Doherty; Michael Ritt; Sivaraj Sivaramakrishnan; Maria G Castro; Pedro R Lowenstein
Journal:  Cancer Res       Date:  2014-07-18       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.